These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 25621884

  • 21. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
    Chanthavanich P, Anderson E, Kerdpanich P, Bulitta M, Kanesa-Thasan N, Hohenboken M.
    Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
    [Abstract] [Full Text] [Related]

  • 22. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
    Czajka H, Unal S, Ulusoy S, Usluer G, Strus A, Sennaroglu E, Guzik J, Topeli Iskit A, Dargiewicz A, Musial D, Caylan R, Dziduch J, Eskioglu E, Hasiec B, Cwinarowiczliwa E, Belli R, Abdel-Messih IA, Beygo J, Fragapane E.
    J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
    [Abstract] [Full Text] [Related]

  • 23. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.
    Vaccine; 2013 Sep 13; 31(40):4389-97. PubMed ID: 23856331
    [Abstract] [Full Text] [Related]

  • 24. Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children.
    Nolan T, Bravo L, Ceballos A, Mitha E, Gray G, Quiambao B, Patel SS, Bizjajeva S, Bock H, Nazaire-Bermal N, Forleo-Neto E, Cioppa GD, Narasimhan V.
    Vaccine; 2014 Oct 21; 32(46):6146-56. PubMed ID: 25223266
    [Abstract] [Full Text] [Related]

  • 25. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY, Cheong HJ, Noh JY, Seo YB, Choi WS, Cho GJ, Hwang TG, Kim WJ.
    J Med Virol; 2013 Sep 21; 85(9):1591-7. PubMed ID: 23852684
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine and an MF59-adjuvanted influenza vaccine after concomitant vaccination in ⩾60-year-old adults.
    Song JY, Cheong HJ, Hyun HJ, Seo YB, Lee J, Wie SH, Choi MJ, Choi WS, Noh JY, Yun JW, Yun JG, Kim WJ.
    Vaccine; 2017 Jan 05; 35(2):313-320. PubMed ID: 27919632
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Comparison of the long-term immunogenicity of two pandemic influenza A/H1N1 2009 vaccines, the MF59-adjuvanted and unadjuvanted vaccines, in adults.
    Song JY, Cheong HJ, Seo YB, Kim IS, Noh JY, Heo JY, Choi WS, Lee J, Kim WJ.
    Clin Vaccine Immunol; 2012 May 05; 19(5):638-41. PubMed ID: 22379067
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S, Pugni L, Daleno C, Ronchi A, Valzano A, Serra D, Mosca F, Principi N.
    Pediatrics; 2011 May 05; 127(5):e1161-8. PubMed ID: 21464195
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in healthy adults: A phase I/II, observer-blind, randomized, controlled trial.
    Madan A, Ferguson M, Sheldon E, Segall N, Chu L, Toma A, Rheault P, Friel D, Soni J, Li P, Innis BL, Schuind A.
    Vaccine; 2017 Mar 07; 35(10):1431-1439. PubMed ID: 28187952
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
    Bihari I, Pánczél G, Kovacs J, Beygo J, Fragapane E.
    Clin Vaccine Immunol; 2012 Dec 07; 19(12):1943-8. PubMed ID: 23081815
    [Abstract] [Full Text] [Related]

  • 40. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D, Campbell P, Hoschler K, Hidalgo L, Al-Dabbagh M, Wilson L, Humar A.
    Transplantation; 2016 Mar 07; 100(3):662-9. PubMed ID: 26335915
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.